Compare JXG & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JXG | PLYX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.6M | 112.7M |
| IPO Year | 2012 | 2025 |
| Metric | JXG | PLYX |
|---|---|---|
| Price | $6.65 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 23.1K | ★ 52.2K |
| Earning Date | 05-14-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $1.85 |
| 52 Week High | $12.00 | $9.18 |
| Indicator | JXG | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 30.44 | 49.61 |
| Support Level | $6.19 | $2.03 |
| Resistance Level | $10.09 | $2.39 |
| Average True Range (ATR) | 0.87 | 0.10 |
| MACD | -0.23 | 0.02 |
| Stochastic Oscillator | 2.76 | 60.66 |
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products. The Company's operations are located in the PRC and all of the Company's revenue is derived from sales to customers in the PRC region.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.